At last, a conservative news aggregator that does not bow to the woke right.
In this ZeroHedge article, staff writers explain why Big Pharma is structurally disincentivized from developing and marketing affordable anti-aging treatments despite scientific potential.
- Pharmaceutical companies prioritize high-margin, patent-protected drugs for chronic conditions over one-time or low-cost interventions that could cure or prevent disease.
- Anti-aging therapies threaten recurring revenue streams from treatments for age-related illnesses like cancer, heart disease, and neurodegeneration, which generate billions annually.
- Regulatory hurdles, including lengthy FDA approval processes and requirements for specific disease indications rather than general “aging,” make broad anti-aging drugs economically unviable.
- Existing business models favor expensive biologics and maintenance therapies; a cheap, effective anti-aging pill would cannibalize multiple profitable drug categories.
- Investment flows toward incremental symptom management rather than root-cause longevity solutions, as the latter risks disrupting entrenched profit centers.
- Potential breakthroughs in senolytics, NAD boosters, or rapamycin analogs face funding and commercialization barriers due to misalignment with Big Pharma’s patent-and-profit incentives.
- Patients and society bear the cost of delayed innovation, while the industry focuses on managing rather than eradicating aging-related decline.
Read the full story:
https://www.zerohedge.com/medical/why-big-pharma-will-never-make-cheap-anti-aging-drug
Biblical worldview. Conservative perspectives. All the links from across the web that Patriots need updated throughout the day in one spot.
